UNCOVERED: 4 | History Defined

4 Best Biotech Stocks According to POWR Ratings

Rapid advancements and soaring demand make the biotech sector well-positioned to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stocks Amgen Inc. (AMGN), Regeneron Pharmaceuticals (REGN), United Therapeutics (UTHR), and Vanda Pharmaceuticals (VNDA) with “Strong Buy” ratings could be wise portfolio additions now. Read on….

StockNews.com · May 23, 2023

Stocks Set to Open Mixed as Investors Weigh Fed Comments and Economic Outlook, Apple Earnings on Tap

June S&P 500 futures (ESM23) are down -0.04%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.20% this morning after three major U.S. benchmark indices ended the regular session in the red as market participants digested Federal Reserve Chair Jerome Powell’s comments following the central bank’s widely expected 25…

Barchart · May 4, 2023

A Prescription for Success: Check Out This Strong Pharmaceutical Stock This Week

Leading biotech company Regeneron Pharmaceuticals (REGN) has exhibited robust financial growth in recent years. With the biotech industry’s promising prospects, this stock might be a solid portfolio addition now. Read on….

StockNews.com · Apr 27, 2023

What Are Whales Doing With Regeneron Pharmaceuticals

A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange trades.

Benzinga · Sep 1, 2022

3 Biotech Stocks to Beat the Bear Market

2022 is a challenging year for the market. After battling surging inflation for the first six months, another threat is emerging with rising recession risk. Biotech stocks could be a place where investors can find outperformance given their low valuations and strong long-term fundamentals.

StockNews.com · Jul 16, 2022

What Are Whales Doing With Regeneron Pharmaceuticals

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 52 strange trades.

Benzinga · Jul 12, 2022

This Foreboding Sign Looms Over Regeneron Pharmaceuticals's Chart

If history is any guide, there may be trouble ahead for shares of Regeneron Pharmaceuticals (NASDAQ:REGN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga · Jul 5, 2022

Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.19% on an annualized basis producing an average annual return of 21.3%. Currently, Regeneron Pharmaceuticals has a market capitalization of $65.05 billion.

Benzinga · Jul 1, 2022

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis.  Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data,…

Benzinga · Jun 24, 2022

Regeneron Pharmaceuticals Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 34 strange trades.

Benzinga · Jun 17, 2022